Addario Lung Cancer Medical Institute Looks into the Genomics of Young Lung Cancer

Thursday, September 25, 2014
Lung cancer at any age is a catastrophic illness but it is particularly devastating when it affects young adults in the prime of their life.

In other cancers, such as breast cancer and leukemia, research has clearly demonstrated that occurrence at a younger age is associated with a distinct biology that guides treatment. Thus, development of a unique treatment approach for young lung cancer is needed.

The Genomics of Young Lung Cancer study, facilitated by the patient-founded Addario Lung Cancer Medical Institute, is an international, prospective genomic analysis of primary lung cancer occurring in patients diagnosed at age less than 40 years in order to provide new insight into lung cancer biology, facilitate the identification of new genome-defined subtypes of lung cancer, accelerate delivery of targeted therapies and lay the groundwork for further studies of lung cancer risk and inheritance.

Patients may participate remotely via https://www.openmednet.org/site/alcmi-goyl.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.